Peter Grell MD· @GrellMd · X·· 14 小时前评分70
正文 · 原文
Phase 3 results from the INTerpath-001 trial confirm that the individualized mRNA vaccine plus pembrolizumab significantly improves outcomes in adjuvant treatment of malignant melanoma.
The era of mRNA vaccines in oncology has officially begun!👏
#ESMO26!
47 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：Peter Grell MD · x.com